PSNL
Personalis, Inc. Health Care Services-Medical Laboratories Russell 3000
$15.82Close
$1.6BMarket cap
$5.04 – $18.3852-week range
Nov 3, 2026Next report
Highlights
Strengths
- Leading the market RS 96 · stronger than 96% of stocks over 12 months
Cautions
- Trend not confirmed 7 of 8 conditions · under the 50-day
- Results soon Nov 3, 2026, in 2 days
- Financial distress Altman Z″ in the distress zone
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
14%
1wk
down 0.2%
price change
1mo
down 2.8%
price change
12-month return
up 66%
market up 11% ·
its own up 55%
F-score
4 / 9
Weak
Altman Z″
0.31
Elevated risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
6.2×
price / book
Earnings yield
down 5.9%
EBIT / enterprise value
Cheaper than
17%
of the market · expensive
Revenue growth
down 18%
year on year
EPS growth
—
latest quarter
Sales growth
up 30%
latest quarter · +55 pts
ROE
down 35%
return on equity
Free cash margin
down 114%
-$79.5M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
Lossoperating loss
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- issued more shares
- gross margin narrowed
- assets working less efficiently
- profitability improving
- profits backed by cash
- reduced long-term debt
- short-term liquidity improved
Trade setup
ATR%
2.2%
$0.34 a day · 2×ATR $15.13
RS
96 / 99
vs the universe
Trend
7 / 8
under the 50-day
Relative volume
0.9×
vs 50-day average
Up/down volume
1.03
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Contractions
2
16% → 8%
Pivot
$16.77
5.7% below
Volume dry-up
0.8×
10 vs 50 sessions
Trend template · 7 of 8
- Price above the 50-day average: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Bankruptcy model reads distressed The Altman score sits inside the range historically associated with financial distress. It is used here only to exclude, never to rank, and it is a statistical band rather than a prediction about this company.
- Losing money before interest is even paid The company made an operating loss, so interest is not covered at all - the debt is being serviced from cash reserves, asset sales or new borrowing rather than from the business.
- Shareholders diluted The share count rose 20.3% over the year, from 85m to 102m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
- Gross margin narrowing Gross margin fell from 31.7% to 22.7%. The company is keeping less of each dollar of sales than it did a year ago.
- Revenue shrinking Revenue fell 17.7% over the year, from $84.6M to $69.6M.
Last reported
Aug 4, 2026
Last shock
Jul 20, 2026-13% in one session2.5× volumeon an SEC filing+19% since
Financials
- Gross 23%
- Net -117%
- Free cash -114%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $78.6M | $85.5M | $65.0M | $73.5M | $84.6M | $69.6M |
| Gross margin | 26% | 37% | 21% | 25% | 32% | 23% |
| Operating income | -$42.1M | -$65.4M | -$115.5M | -$109.9M | -$68.3M | -$88.1M |
| Net income | -$41.3M | -$65.2M | -$113.3M | -$108.3M | -$81.3M | -$81.3M |
| Net margin | -52% | -76% | -174% | -147% | -96% | -117% |
| Earnings per share | -$1.20 | -$1.49 | -$2.48 | -$2.25 | -$1.37 | -$0.91 |
| Free cash flow | -$45.9M | -$81.9M | -$120.1M | -$67.2M | -$46.8M | -$79.5M |
| Free cash margin | -58% | -96% | -185% | -91% | -55% | -114% |
| Cash | $68.5M | $105.6M | $89.1M | $57.0M | $91.4M | $124.2M |
| Long-term debt | $0 | — | — | — | — | — |
| Shareholders' equity | $194.9M | $310.3M | $218.1M | $129.4M | $203.0M | $261.2M |
| Shares outstanding | 39.11m | 44.90m | 46.71m | 50.48m | 85.17m | 102.48m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 7, 2026 | Quarterly ↗ | Mar 31, 2026 | 37d |
| Feb 26, 2026 | Annual ↗ | Dec 31, 2025 | 57d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 27, 2025 | Annual ↗ | Dec 31, 2024 | 58d |
| Nov 6, 2024 | Quarterly ↗ | Sep 30, 2024 | 37d |
| Aug 7, 2024 | Quarterly ↗ | Jun 30, 2024 | 38d |
| May 8, 2024 | Quarterly ↗ | Mar 31, 2024 | 38d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 7, 2023 | Quarterly ↗ | Sep 30, 2023 | 38d |
Current reports
| Filed | Disclosed |
|---|---|
| Oct 6, 2026 | Other events ↗ |
| Aug 20, 2026 | Other events ↗ |
| Aug 4, 2026 | Results ↗ |
| Jul 20, 2026 | Material agreement ↗ |
| Jul 20, 2026 | Results · Regulation FD ↗ |
| May 20, 2026 | Other events ↗ |
| May 13, 2026 | Shareholder vote ↗ |
| May 13, 2026 | Other events ↗ |
| May 7, 2026 | Results ↗ |
| Mar 17, 2026 | Director or officer change ↗ |
| Feb 26, 2026 | Results ↗ |
| Jan 8, 2026 | Results ↗ |